Leukemia: Why Gleevec Got Approved

When officials at the FDA take just 2 1/2 months to approve a new cancer treatment, you know it's got to be some kind of breakthrough. And indeed the drug called Gleevec, which was given the go-ahead last week in record time, has produced dramatic results in patients with a rare malignancy called chronic myeloid leukemia. It's too early to say just how good Gleevec is. But the drug's success so far makes one thing clear. When designing a safe, effective treatment for a particular cancer, it pays to learn as much as possible about its underlying molecular biology.

Chronic myeloid...

Want the full story?

Subscribe Now


Get TIME the way you want it

  • One Week Digital Pass — $4.99
  • Monthly Pay-As-You-Go DIGITAL ACCESS$2.99
  • One Year ALL ACCESSJust $30!   Best Deal!
    Print Magazine + Digital Edition + Subscriber-only Content on TIME.com

Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!